2016 In Review: FDA Transparency, Claims Enforcement A One-Off?

The Rose Sheet’s coverage of FDA’s warning letter crackdown and data sharing produced some of its most-read stories of 2016, based on online analytics. Legislative proposals and cosmetic safety issues in the US mainstream factored in the agency’s transparency work, a situation that may not repeat in the new year.